S Shoham1, D Ostrander1, K Marr1. 1. Transplant and Oncology Infectious Diseases Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Posaconazole (PCZ) has become an attractive alternative to voriconazole (VCZ) in transplant recipients with suspected or proven invasive filamentous fungal infections, causing fewer drug interactions. Here, we describe our experience with PCZ after VCZ in solid organ transplant (SOT) recipients. METHODS: VCZ was replaced by PCZ liquid solution in 19 SOT recipients (15 lung, 2 kidney, 1 liver, and 1 heart/lung) with invasive pulmonary aspergillosis (12/19; 63.2%), possible invasive pulmonary fungal infection (2/19; 10.5%), prophylaxis (2/19; 10.5%), or pulmonary scedosporiosis, mucormycosis, and mixed fungal species (1 each). Rationales for switch were suspected adverse reactions to VCZ (17/19; 89.4%) and desire to broaden spectrum of coverage to include agents of mucormycosis (3/19; 15.8%). RESULTS: PCZ was well tolerated in all patients. In those patients with baseline liver enzyme abnormalities, a median change occurred in concentrations of alanine transaminase (-20 IU/L), aspartate aminotransferase (-17.5 IU/L), and alkaline phosphatase (-61.5 IU/L). Clinical success (resolution, stabilization, or prevention of infection) was achieved in 16/19 (84%) people. CONCLUSION: PCZ appears to have a reasonable safety and tolerability profile and may be an effective alternative in SOT patients who require an agent with anti-mold activity, but are unable to tolerate VCZ.
BACKGROUND:Posaconazole (PCZ) has become an attractive alternative to voriconazole (VCZ) in transplant recipients with suspected or proven invasive filamentous fungal infections, causing fewer drug interactions. Here, we describe our experience with PCZ after VCZ in solid organ transplant (SOT) recipients. METHODS:VCZ was replaced by PCZ liquid solution in 19 SOT recipients (15 lung, 2 kidney, 1 liver, and 1 heart/lung) with invasive pulmonary aspergillosis (12/19; 63.2%), possible invasive pulmonary fungal infection (2/19; 10.5%), prophylaxis (2/19; 10.5%), or pulmonary scedosporiosis, mucormycosis, and mixed fungal species (1 each). Rationales for switch were suspected adverse reactions to VCZ (17/19; 89.4%) and desire to broaden spectrum of coverage to include agents of mucormycosis (3/19; 15.8%). RESULTS:PCZ was well tolerated in all patients. In those patients with baseline liver enzyme abnormalities, a median change occurred in concentrations of alanine transaminase (-20 IU/L), aspartate aminotransferase (-17.5 IU/L), and alkaline phosphatase (-61.5 IU/L). Clinical success (resolution, stabilization, or prevention of infection) was achieved in 16/19 (84%) people. CONCLUSION:PCZ appears to have a reasonable safety and tolerability profile and may be an effective alternative in SOT patients who require an agent with anti-mold activity, but are unable to tolerate VCZ.
Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: Timothy W Felton; Caroline Baxter; Caroline B Moore; Stephen A Roberts; William W Hope; David W Denning Journal: Clin Infect Dis Date: 2010-11-05 Impact factor: 9.079
Authors: Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect Journal: Clin Infect Dis Date: 2006-11-28 Impact factor: 9.079
Authors: Brahm H Segal; Lisa A Barnhart; Victoria L Anderson; Thomas J Walsh; Harry L Malech; Steven M Holland Journal: Clin Infect Dis Date: 2005-04-29 Impact factor: 9.079
Authors: Issam I Raad; John R Graybill; Ana Beatriz Bustamante; Oliver A Cornely; Veronica Gaona-Flores; Claude Afif; Donald R Graham; Richard N Greenberg; Susan Hadley; Amelia Langston; Ricardo Negroni; John R Perfect; Punnee Pitisuttithum; Angela Restrepo; Gary Schiller; Lisa Pedicone; Andrew J Ullmann Journal: Clin Infect Dis Date: 2006-05-08 Impact factor: 9.079
Authors: Barbara D Alexander; John R Perfect; Jennifer S Daly; Angela Restrepo; Angela M Tobón; Hernando Patino; Catherine J Hardalo; John R Graybill Journal: Transplantation Date: 2008-09-27 Impact factor: 4.939
Authors: Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis Journal: Clin Infect Dis Date: 2006-02-21 Impact factor: 9.079
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079